Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.95 EUR | +0.85% |
|
-0.84% | -10.61% |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The firm trades with high earnings multiples: 31.27 times its 2025 earnings per share.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-10.61% | 584M | - | ||
+3.74% | 104B | A- | ||
-10.18% | 59.99B | A- | ||
+80.95% | 50.92B | B | ||
+8.46% | 36.09B | B | ||
-0.02% | 30.95B | A- | ||
+4.78% | 18.85B | B- | ||
+18.14% | 17.61B | C+ | ||
+9.26% | 13.97B | B- | ||
+78.32% | 13B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 3101 Stock
- TO7 Stock
- Ratings Toyobo Co., Ltd.